Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs
November 10, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be...
Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid
November 03, 2022 08:45 ET
|
Love Pharma Inc.
NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, has been explicit about its plans to develop a...
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
November 03, 2022 08:00 ET
|
Daxor Corporation
Study Highlighted That Only The BVA-100 Accurately Measures Volume Derangements Compared to Commonly Used Surrogates Oak Ridge, TN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq:...
US Military Health System Research Study Deploys Clinical ink's Self-Testing Mobile Platform to Understand Long COVID
November 01, 2022 12:28 ET
|
Clinical Ink
Horsham, Pennsylvania, USA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, has developed a self-testing app to measure cognitive impairment in patients...
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
October 31, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart...
InvestmentPitch Media Video Discusses LOVE Pharma’s Pending Acquisition of Naltrexone Therapeutics Supported by Reports that Naltrexone Demonstrates Promising Long COVID Applications
October 21, 2022 06:00 ET
|
InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) which on October 11th signed a nonbinding Letter of Intent to acquire 100% of Naltrexone Therapeutics,...
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting
October 05, 2022 08:30 ET
|
Daxor Corporation
Evidence Presented Utilizing Daxor’s BVA-100® Blood Volume Test Oak Ridge, TN, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
October 04, 2022 08:30 ET
|
Daxor Corporation
The Premier Event For The Cardiovascular Industry's Leading Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically Improve Their Business and...
Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting
October 04, 2022 08:00 ET
|
Daxor Corporation
Traditional Care: More than 50% Discharged From Hospital With Suboptimal Treatment Oak Ridge, TN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood...
New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%
October 03, 2022 09:00 ET
|
Daxor Corporation
Patients Receiving BVA Stayed 2.5 Fewer Days in Hospital Resulting in Reduced Costs of Care Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation, the global leader in blood volume...